GALVANI, Elena
 Distribuzione geografica
Continente #
EU - Europa 323
NA - Nord America 274
AS - Asia 137
AF - Africa 8
OC - Oceania 1
Totale 743
Nazione #
US - Stati Uniti d'America 272
FI - Finlandia 107
CN - Cina 101
IE - Irlanda 62
SE - Svezia 55
IT - Italia 49
DE - Germania 29
TR - Turchia 17
SG - Singapore 16
UA - Ucraina 12
CI - Costa d'Avorio 8
BE - Belgio 5
IN - India 3
CA - Canada 2
FR - Francia 2
LU - Lussemburgo 1
NL - Olanda 1
NZ - Nuova Zelanda 1
Totale 743
Città #
Chandler 62
Dublin 62
Parma 30
Jacksonville 27
Beijing 23
Ann Arbor 22
Dearborn 22
Izmir 17
Shanghai 16
Ashburn 15
Boardman 14
Nanjing 14
Singapore 13
San Mateo 10
Abidjan 8
Bremen 8
New York 8
Princeton 8
Seattle 7
Hebei 6
Brussels 5
Kunming 5
Shenyang 5
Helsinki 4
Jinan 4
Düsseldorf 3
Jiaxing 3
Munich 3
Wilmington 3
Changsha 2
Des Moines 2
Gainesville 2
Grafing 2
Guangzhou 2
Hangzhou 2
Leawood 2
Mestre 2
Milan 2
Norwalk 2
Pune 2
Redwood City 2
Shaoxing 2
Tianjin 2
Toronto 2
Auckland 1
Augusta 1
Bologna 1
Borås 1
Chengdu 1
Chongqing 1
Fuzhou 1
Hefei 1
Huizen 1
Lissone 1
Los Angeles 1
Luxembourg 1
Modena 1
Monmouth Junction 1
Montegaldella 1
Mountain View 1
Nanchang 1
Ningbo 1
Santa Clara 1
Sassuolo 1
Taizhou 1
Torre Annunziata 1
Woodbridge 1
Totale 480
Nome #
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 105
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 89
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 87
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 84
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 81
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 79
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 73
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 69
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling 54
null 31
Totale 752
Categoria #
all - tutte 2.647
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.647


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202086 0 0 4 2 8 14 24 2 13 5 5 9
2020/202146 1 4 2 1 7 0 3 0 12 4 12 0
2021/202246 2 0 0 7 1 2 5 5 3 5 6 10
2022/2023221 19 24 18 22 20 25 1 13 71 0 5 3
2023/202479 2 9 3 3 7 18 5 16 4 1 3 8
2024/202535 9 12 14 0 0 0 0 0 0 0 0 0
Totale 752